Shares of Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) traded down 1.7% during mid-day trading on Tuesday . The company traded as low as $1.58 and last traded at $1.76. 20,514 shares were traded during trading, a decline of 16% from the average session volume of 24,454 shares. The stock had previously closed at $1.79.
Humacyte Stock Performance
The stock has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $1.96.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- What Are Trending Stocks? Trending Stocks Explained
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Health Care Stocks Explained: Why You Might Want to Invest
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What Is WallStreetBets and What Stocks Are They Targeting?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
